Profile data is unavailable for this security.
About the company
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2010
- Employees1.00
- LocationAptorum Group Ltd17 Hanover SquareLONDON W1S 1BNUnited KingdomGBR
- Phone+44 208 092 9299
- Fax+44 203 928 8277
- Websitehttps://www.aptorumgroup.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 5.70m | 28.00 | -- | 0.7933 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -9.25m | 5.75m | 11.00 | -- | 0.773 | -- | -- | -25.21 | -25.21 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -125.80 | -- | -221.96 | -- | -- | -- | -- | -- | -- | -84.50 | 0.1808 | -- | -- | -- | -223.39 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.86m | -3.16m | 5.80m | 2.00 | -- | 0.9867 | -- | 2.03 | -2.05 | -2.05 | 1.85 | 2.57 | 0.436 | -- | -- | 1,429,470.00 | -48.14 | -42.99 | -57.42 | -46.44 | -- | -- | -110.40 | -373.71 | -- | -- | 0.00 | -- | -1.56 | 171.11 | 4.22 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.33m | 4.00 | -- | 0.8353 | -- | 1,054.23 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.35m | 1.00 | -- | 0.2474 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 6.41m | 8.00 | -- | 0.5023 | -- | 13.13 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| Moleculin Biotech Inc | 0.00 | -41.36m | 6.44m | 17.00 | -- | -- | -- | -- | -55.88 | -55.88 | 0.00 | -13.60 | 0.00 | -- | -- | 0.00 | -189.07 | -49.52 | -254.72 | -54.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 26.89 | -- | -24.21 | -- |
| BioNexus Gene Lab Corp | 9.47m | -2.30m | 6.44m | 30.00 | -- | 0.718 | -- | 0.6803 | -1.28 | -1.28 | 5.27 | 3.79 | 1.02 | 6.73 | 6.42 | -- | -24.68 | -6.00 | -27.80 | -7.75 | 14.77 | 14.31 | -24.27 | -4.98 | 6.81 | -1,354.05 | 0.00 | -- | -2.66 | 137.09 | 39.20 | -- | 77.67 | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 6.56m | 37.00 | -- | 0.1961 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Bullfrog AI Holdings Inc | 116.67k | -6.76m | 6.61m | 9.00 | -- | 3.11 | -- | 56.68 | -0.6936 | -0.6936 | 0.0119 | 0.1866 | 0.0319 | -- | -- | 12,963.33 | -184.34 | -- | -233.50 | -- | 18.76 | -- | -5,770.66 | -- | -- | -- | 0.0278 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
| Biomx Inc | 0.00 | -36.20m | 6.96m | 20.00 | -- | -- | -- | -- | -23.69 | -23.69 | 0.00 | -0.817 | 0.00 | -- | -- | 0.00 | -147.70 | -62.93 | -210.64 | -78.33 | -- | -- | -- | -- | -- | -41.56 | -- | -- | -- | -- | -104.20 | -- | -71.20 | -- |
| Aspire Biopharma Holdings Inc | 1.94k | -28.70m | 6.98m | -- | -- | -- | -- | 3,599.77 | -65.96 | -65.96 | 0.0022 | -9.26 | 0.0004 | -- | -- | -- | -633.21 | -- | -- | -- | 45.36 | -- | -1,479,598.00 | -- | 0.1708 | -6.20 | -- | -- | -- | -- | -380.85 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 6.99m | 2.00 | -- | 0.1315 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -56.98m | 7.00m | 36.00 | -- | 6.47 | -- | -- | -1.22 | -1.22 | 0.00 | 0.0194 | 0.00 | -- | -- | 0.00 | -48.20 | -42.95 | -55.60 | -46.33 | -- | -- | -- | -- | -- | -- | 0.943 | -- | -- | -- | -81.07 | -- | 36.12 | -- |
Data as of Mar 02 2026. Currency figures normalised to Aptorum Group Ltd's reporting currency: US Dollar USD
8.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| L1 Capital Global, Inc.as of 30 Apr 2025 | 383.75k | 6.05% |
| Citadel Securities LLCas of 31 Dec 2025 | 115.58k | 1.82% |
| Two Sigma Investments LPas of 31 Dec 2025 | 17.41k | 0.27% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 13.30k | 0.21% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2025 | 5.50k | 0.09% |
| UBS Securities LLCas of 31 Dec 2025 | 2.25k | 0.04% |
| BNP Paribas Financial Marketsas of 31 Dec 2025 | 400.00 | 0.01% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 7.00 | 0.00% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 14 Feb 2026Source: FactSet Research Systems Inc.
